It’s the first of its kind! SIMPONI Golimumab is the first to offer a monthly dosing of self-injectable anti–TNF-alpha therapy approved to treat adults with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), and Ankylosing Spondylitis (AS).
Although the effect varies on a case to case basis, SIMPONI can provide initial relief to the signs and symptoms of RA, PsA, and AS. You will feel a difference in just as little as four weeks starting from the day of the first therapy.